Physician profile
Robert E Burr
NPI 1770533788
$1,793.80
in general payments reported to CMS, 2019-2025
23 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $35.09 · 2021: $72.69 · 2022: $11.71 · 2023: $244 · 2024: $403 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $286.65 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $258.96 | 2019-2024 | Evenity, Prolia, Tezspire |
| Lilly USA, LLC | $243.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $172.56 | 2019-2024 | |
| Dexcom, INC. | $118.18 | 2019-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $101.48 | 2019-2024 | Freestyle Libre 3 |
| Insulet Corporation | $89.05 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.67 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $59.07 | 2019-2024 | Fasenra |
| Janssen Pharmaceuticals, INC | $58.72 | 2019 | |
| Shire North American Group INC | $43.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.81 | 2024-2025 | |
| Amarin Pharma, INC. | $38.31 | 2019-2020 | |
| Radius Health, INC. | $30.35 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.02 | 2023 | Strensiq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $28.21 | 2019 | |
| Senseonics, Incorporated | $28.00 | 2019 | |
| Tandem Diabetes Care, INC. | $25.22 | 2019 | |
| Medtronic, INC. | $21.61 | 2024 | Minimed 780g |
| Kyowa Kirin, INC. | $18.20 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $16.37 | 2019 | |
| Viiv Healthcare Company | $14.63 | 2024 | Dovato, Cabenuva |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Burr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.